Publications by authors named "Mahran Shoukier"

Claim this Profile
G
Global Trial Representation and Availability of Tyrosine Kinase Inhibitors for Treatment of Chronic Myeloid Leukemia.
Mycal Casey, Lorriane Odhiambo, Nidhi Aggarwal, Mahran Shoukier, K M Islam

Cancers (Basel)· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns and outcomes of high-grade immune checkpoint inhibitor-related pneumonitis in an oncology hospitalist service.
Joanna-Grace M Manzano, Hadeel Sahar, Jeffrey Aldrich, Maggie Lu, Mahran Shoukier

Support Care Cancer· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Industry's role in HIV, hepatitis B, and hepatitis C exclusion in AML and MDS clinical trials.
Tahsin Anwar, Sean Malhotra, Mohammad A H Mian, Tahiya Anwar, Vamsi Kota, Mahran Shoukier

Hematology· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Representation of the population in need for pivotal clinical trials in lymphomas.
Mycal Casey, Lorriane Odhiambo, Nidhi Aggarwal, Mahran Shoukier, K M Islam

Blood· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study of the Non-Receptor Kinase Inhibitor Bosutinib in Combination with Pemetrexed in Patients with Selected Metastatic Solid Tumors.
Nagla Abdel Karim, Asad Ullah, Hongkun Wang, Mahran Shoukier, Steven Pulliam

Curr Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are Pivotal Clinical Trials for Drugs Approved for Leukemias and Multiple Myeloma Representative of the Population at Risk?
Mycal Casey, Lorriane Odhiambo, Nidhi Aggarwal, Mahran Shoukier, Jamani Garner

J Clin Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia.
Jayastu Senapati, Mahran Shoukier, Guillermo Garcia-Manero, Xuemei Wang, Keyur Patel

Am J Hematol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis.
Mahran Shoukier, Gautam Borthakur, Elias Jabbour, Farhad Ravandi, Guillermo Garcia-Manero

Haematologica· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy.
Sangeetha Venugopal, Mahran Shoukier, Marina Konopleva, Courtney D Dinardo, Farhad Ravandi

Cancer· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sudden Blast Crisis After Excellent Initial Response in Chronic Myeloid Leukemia.
Aviraag Vijaya Prakash, Keerthana P Sivakolundu, Natasha M Savage, Vamsi K Kota, Mahran Shoukier

Cureus· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Review of New-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.
Mahran Shoukier, Michal Kubiak, Jorge Cortes

Curr Oncol Rep· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors.
Jeffrey Aldrich, Xerxes Pundole, Sudhakar Tummala, Nicolas Palaskas, Clark R Andersen, Mahran Shoukier

Arthritis Rheumatol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
Mahran Shoukier, Tapan Kadia, Marina Konopleva, Ahmad S Alotaibi, Mansour Alfayez

Cancer· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation.
Chantal Saberian, Noha Abdel-Wahab, Ala Abudayyeh, Hind Rafei, Jacinth Joseph, Mahran Shoukier

J Immunother Cancer· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia.
Maro Ohanian, Hagop M Kantarjian, Mahran Shoukier, Sara Dellasala, Arine Musaelyan

Am J Hematol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Major Stressful Life Events and Risk of Developing Lung Cancer: A Case-Control Study.
Syed H Jafri, Faisal Ali, Arash Mollaeian, Syed Mojiz Hasan, Rahat Hussain, Mahran Shoukier

Clin Med Insights Oncol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study.
Asifa Malik, Mahran Shoukier, Guillermo Garcia-Manero, William Wierda, Jorge Cortes

Clin Lymphoma Myeloma Leuk· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis